Most Common Adverse Events (AEs) in CIC1 CIC
AE Trulance 3 mg
(n=863)
%
Placebo
(n=870)
%
Diarrhea 5.0 1.0
  • Severe diarrhea was reported in 0.6% of patients receiving Trulance vs 0.3% of placebo-treated patients
4% discontinuation rate for Trulance vs 2% for placebo
  • 2% discontinuation rate due to diarrhea vs 0.5% for placebo
Most Common AEs in IBS-C1 IBS-C
AE Trulance 3 mg
(n=723)
%
Placebo
(n=726)
%
Diarrhea 4.3 1.0
  • Severe diarrhea was reported in 1% of patients receiving Trulance vs 0.1% of placebo-treated patients
2.5% discontinuation rate for Trulance vs 0.4% for placebo
  • 1.2% discontinuation rate due to diarrhea vs 0% for placebo
  • If severe diarrhea occurs, suspend dosing and rehydrate the patient1
  • No additional AEs occurred at an incidence of ≥2% of patients treated with Trulance and at an incidence greater than placebo1
  • Minimally absorbed with negligible systemic availability1
  • No drug-drug interactions1